Free tool
FAERS Monitor: Zovirax
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018604 or its brand name (Zovirax, Acyclovir). Reports on generic versions are filed under their own applications.
Reports
115,336
Serious
83,639
73% of reports
Hospitalization
42,811
Death reported
14,680
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue8,096
- diarrhoea7,417
- off label use6,407
- pneumonia5,695
- nausea5,651
- pyrexia4,977
- death4,923
- drug ineffective4,759
- rash4,308
- dyspnoea3,608
- asthenia3,360
- headache3,298
- neutropenia3,274
- white blood cell count decreased3,223
- platelet count decreased3,097
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 879 |
| 2005 | 1,014 |
| 2006 | 1,020 |
| 2007 | 1,070 |
| 2008 | 1,327 |
| 2009 | 1,364 |
| 2010 | 1,424 |
| 2011 | 2,412 |
| 2012 | 2,446 |
| 2013 | 1,808 |
| 2014 | 2,467 |
| 2015 | 5,584 |
| 2016 | 5,828 |
| 2017 | 6,979 |
| 2018 | 8,210 |
| 2019 | 9,100 |
| 2020 | 9,880 |
| 2021 | 11,357 |
| 2022 | 10,637 |
| 2023 | 8,757 |
| 2024 | 8,201 |
| 2025 | 8,328 |
| 2026 | 5,242 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,938,823 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| white blood cell count decreasedSignal | 3,223 | 5.6 | 5.4 | 11,744 |
| platelet count decreasedSignal | 3,097 | 5.4 | 5.2 | 10,911 |
| neutropeniaSignal | 3,274 | 4.5 | 4.3 | 8,674 |
| pneumoniaSignal | 5,695 | 3.2 | 3.2 | 8,835 |
| pyrexiaSignal | 4,977 | 2.6 | 2.6 | 5,108 |
| diarrhoeaSignal | 7,417 | 2.1 | 2.1 | 4,405 |
| fatigue | 8,096 | 1.9 | 1.9 | 3,581 |
| rash | 4,308 | 1.8 | 1.8 | 1,579 |
| asthenia | 3,360 | 1.6 | 1.6 | 836 |
| off label use | 6,407 | 1.3 | 1.3 | 563 |
| nausea | 5,651 | 1.3 | 1.3 | 413 |
| dyspnoea | 3,608 | 1.2 | 1.1 | 84 |
| death | 4,923 | 1.0 | 1.0 | 9 |
| headache | 3,298 | 1.0 | 0.9 | 6 |
| drug ineffective | 4,759 | 0.7 | 0.6 | 904 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.